DNA APTAMERS AND COMPOSITIONS TARGETING ALPHA-SYNUCLEIN AND METHODS OF MAKING AND USING SAME
The present disclosure, in part, relates to novel, aptamers targeting α-synuclein. The present disclosure includes methods for making and methods of using aptamers targeting α-synuclein.
1 . A method of treatment of a subject suffering from a synucleinopathy, comprising the step of administering to the subject a pharmaceutical composition comprising an effective amount of an ssDNA aptamer.
2 . The method of claim 1 , wherein said ssDNA aptamer comprises at least one of Apt3, Apt5, Apt7, Apt9, Apt11, Apt15, Apt18, or Apt20.
3 . The method of claim 2 , wherein said ssDNA aptamer comprises Apt3.
4 . The method of claim 2 , wherein said ssDNA aptamer comprises Apt5.
5 . The method of claim 2 , wherein said ssDNA aptamer comprises Apt7.
6 . The method of claim 2 , wherein said ssDNA aptamer comprises Apt9.
7 . The method of claim 2 , wherein said ssDNA aptamer comprises Apt11.
8 . The method of claim 2 , wherein said ssDNA aptamer comprises Apt15.
9 . The method of claim 2 , wherein said ssDNA aptamer comprises Apt18.
10 . The method of claim 2 , wherein said ssDNA aptamer comprises Apt20.
11 . The method of claim 1 , wherein said synucleinopathy comprises Parkinson's disease (PD).
12 . The method of claim 1 , wherein said synucleinopathy comprises dementia with Lewy bodies.
13 . The method of claim 1 , wherein said synucleinopathy comprises Alzheimer's disease.
14 . The method of claim 1 , wherein said synucleinopathy comprises multiple system atrophy (MSA).
15 . A composition comprising an ssDNA aptamer and a pharmaceutically acceptable carrier.
16 . The composition of claim 15 , wherein said ssDNA aptamer comprises at least one of Apt3, Apt5, Apt7, Apt9, Apt11, Apt15, Apt18, or Apt20.